These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24988476)

  • 1. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.
    Napolitano A; Miller S; Nicholls AW; Baker D; Van Horn S; Thomas E; Rajpal D; Spivak A; Brown JR; Nunez DJ
    PLoS One; 2014; 9(7):e100778. PubMed ID: 24988476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
    Nunez DJ; Bush MA; Collins DA; McMullen SL; Gillmor D; Apseloff G; Atiee G; Corsino L; Morrow L; Feldman PL
    PLoS One; 2014; 9(4):e92494. PubMed ID: 24699248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
    Rohde U
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
    DeFronzo RA; Buse JB; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetologia; 2016 Aug; 59(8):1645-54. PubMed ID: 27216492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids.
    Sansome DJ; Xie C; Veedfald S; Horowitz M; Rayner CK; Wu T
    Diabetes Obes Metab; 2020 Feb; 22(2):141-148. PubMed ID: 31468642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
    Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin.
    Bahne E; Hansen M; Brønden A; Sonne DP; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2016 Oct; 18(10):955-61. PubMed ID: 27265206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas.
    Kuhre RE; Wewer Albrechtsen NJ; Larsen O; Jepsen SL; Balk-Møller E; Andersen DB; Deacon CF; Schoonjans K; Reimann F; Gribble FM; Albrechtsen R; Hartmann B; Rosenkilde MM; Holst JJ
    Mol Metab; 2018 May; 11():84-95. PubMed ID: 29656109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
    Brønden A; Albér A; Rohde U; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4153-4162. PubMed ID: 28938439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duodenal-Jejunal Bypass Preferentially Elevates Serum Taurine-Conjugated Bile Acids and Alters Gut Microbiota in a Diabetic Rat Model.
    Zhang X; Wang Y; Zhong M; Liu T; Han H; Zhang G; Liu S; Wei M; Wu Q; Hu S
    Obes Surg; 2016 Aug; 26(8):1890-9. PubMed ID: 26715331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Triggers PYY Secretion in Human Gut Mucosa.
    Sun EW; Martin AM; Wattchow DA; de Fontgalland D; Rabbitt P; Hollington P; Young RL; Keating DJ
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2668-2674. PubMed ID: 30759215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.
    Tong X; Xu J; Lian F; Yu X; Zhao Y; Xu L; Zhang M; Zhao X; Shen J; Wu S; Pang X; Tian J; Zhang C; Zhou Q; Wang L; Pang B; Chen F; Peng Z; Wang J; Zhen Z; Fang C; Li M; Chen L; Zhao L
    mBio; 2018 May; 9(3):. PubMed ID: 29789365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects.
    Fernández-García JC; Murri M; Coin-Aragüez L; Alcaide J; El Bekay R; Tinahones FJ
    Clin Endocrinol (Oxf); 2014 May; 80(5):671-6. PubMed ID: 23573808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.
    Brønden A; Mikkelsen K; Sonne DP; Hansen M; Våben C; Gabe MN; Rosenkilde M; Tremaroli V; Wu H; Bäckhed F; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2018 Jul; 20(7):1623-1631. PubMed ID: 29493868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery.
    Jensen CZ; Bojsen-Møller KN; Svane MS; Holst LM; Hermansen K; Hartmann B; Wewer Albrechtsen NJ; Kuhre RE; Kristiansen VB; Rehfeld JF; Clausen TR; Holst JJ; Madsbad S
    Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G661-G672. PubMed ID: 32068442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
    Borg MJ; Bound M; Grivell J; Sun Z; Jones KL; Horowitz M; Rayner CK; Wu T
    Diabetes Obes Metab; 2019 Mar; 21(3):640-647. PubMed ID: 30370686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.